OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Katims on Characterizing Immune Phenotype in FGFR3-mutated Upper Tract Urothelial Carcinoma

May 23rd 2023

Andrew Katims, MD, MPH, discusses research characterizing immune responses in the tumor microenvironment of FGFR3-mutated upper tract urothelial carcinoma using single-cell RNA-sequencing

Dr Kin on Clinical Implications of the FDA Approval of Teclistamab in R/R Multiple Myeloma

May 23rd 2023

Andrew Kin, MD, discusses clinical implications of the FDA approval for teclistamab-cqyv in relapsed/refractory multiple myeloma.

Dr Harding on the Rationale for Targeting FGFR2 in Cholangiocarcinoma and Biliary Tract Cancers

May 23rd 2023

James Harding, MD, discusses the rationale for targeting FGFR2 in patients with cholangiocarcinoma and biliary tract cancers.

Dr Cardin on Targeting KRAS in Pancreatic Cancer

May 22nd 2023

Dana B Cardin, MD, MSCI, discusses the rationale for exploring KRAS as a therapeutic target in pancreatic cancer.

Dr Phillips on Treatment After Progression on a BTK Inhibitor in MCL

May 22nd 2023

Tycel Phillips, MD, MPH, discusses treatment options for patients with relapsed/refractory mantle cell lymphoma who have progressed on covalent BTK inhibitors.

Dr Srour on the Mechanism of Action of ALLO-316 in Metastatic Clear Cell RCC

May 22nd 2023

Samer A. Srour, MB ChB, MS, discusses the mechanism of action of ALLO-316, which is being investigated for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma, and details safety findings from the phase 1 TRAVERSE study evaluating ALLO-316 in this patient population.

Dr Grieb on the Importance of Targeting the MYC Oncogene in CRC and Solid Tumors

May 22nd 2023

Brian C. Grieb, MD, PhD, emphasizes the importance of investigating agents that target the MYC oncogene, as well as supportive cofactors, in colorectal cancer and other tumor types.

Dr Tauro on Next Steps for the Investigation of Novel Autophagy Inhibitors in R/R Multiple Myeloma

May 22nd 2023

Marilena Tauro, PhD, discusses next steps planned for the development of novel autophagy inhibitory strategies to combat chemotherapy resistance in relapsed/refractory multiple myeloma.

Dr Cummings on Adjuvant Osimertinib in EGFR-Mutant NSCLC

May 19th 2023

Amy L. Cummings, MD, PhD, discusses key findings from the phase 3 ADAURA trial in patients with non–small cell lung cancer harboring EGFR mutations.

Dr Mohan on CAR T-cell Therapies and Bispecific Antibodies in R/R Multiple Myeloma

May 19th 2023

Meera Mohan, MD, MS, FACP, discusses the significance of CAR T-cell therapies and bispecific antibodies in patients with relapsed/refractory multiple myeloma.

Dr Hilton on the Impact of Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 19th 2023

Christie J. Hilton, DO, discusses the impact of trastuzumab deruxtecan on the treatment of patients with HER2-positive metastatic breast cancer and ongoing research with the agent in this patient population.

Dr Dhanji on Hypertension as a Risk Factor for Mortality in Urothelial Cancer

May 19th 2023

Sohail Dhanji, MD, discusses the investigation of preoperative hypertension as a risk factor in patients undergoing nephroureterectomy for upper tract urothelial carcinoma, as well as other risk factors for mortality in this patient population.

Dr Stone on the Association of Language Barriers and PSA Screening for Prostate Cancer

May 19th 2023

Benjamin V. Stone, MD, discusses the association between language barriers and prostate-specific antigen screening rates in American men.

Dr Rini on the OPTIC RCC Trial in Advanced Kidney Cancer

May 19th 2023

Brian I. Rini, MD, FASCO, discusses efforts to utilize genetic testing to improve treatment selection in renal cell carcinoma through the phase 2 OPTIC RCC trial.

Dr Hays on the Evolution of Later-line Treatment Options in Refractory mCRC

May 19th 2023

John L. Hays, MD, PhD, discusses the evolution of the treatment paradigm for patients with metastatic colorectal cancer who experience disease progression following standard chemotherapy regimens.

Dr Phillips on the FDA Approval of Epcoritamab in R/R DLBCL

May 19th 2023

Tycel Phillips, MD, discusses the significance of the FDA approval of the bispecific antibody epcoritamab in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dr Mascarenhas on Ongoing Research in Myelofibrosis

May 18th 2023

John Mascarenhas, MD, discusses ongoing trials and research in myelofibrosis.

Dr Gupta on the Background of the JAVELIN Bladder 100 Trial in Urothelial Carcinoma

May 18th 2023

Shilpa Gupta, MD, discusses the background of the phase 3 JAVELIN Bladder 100 trial in patients with advanced urothelial carcinoma.

Dr Singer on the Safety of Perioperative Nivolumab and Cabozantinib in RCC

May 18th 2023

Eric A. Singer, MD, discusses the safety of perioperative nivolumab and cabozantinib in patients with metastatic clear cell renal cell carcinoma.

Dr Grieb on MYC in CRC

May 18th 2023

Brian C. Grieb, MD, PhD, discusses historical barriers to targeting the MYC oncogene in patients with colorectal cancer and the rationale for an ongoing phase 1/2 clinical trial that may demonstrate an effective way to target MYC in CRC and other solid tumors.